Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (MVA-SARS2-ST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04895449
Recruitment Status : Recruiting
First Posted : May 20, 2021
Last Update Posted : January 5, 2022
German Center for Infection Research
Philipps University Marburg Medical Center
Ludwig-Maximilians - University of Munich
IDT Biologika
Clinical Trial Center North (CTC North GmbH & Co. KG)
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : March 1, 2022